PharmaEssentia at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
PharmaEssentia brings 2 presentations to ASH 2026 in New Orleans, and exhibits at Booth 3739. Its program centres on myeloproliferative neoplasms, especially essential thrombocythemia and polycythemia vera. It hosts a session on managing essential thrombocythemia and supports symposia on real-world care.
| Organization | ASH 2026 Attendance |
|---|---|
PharmaEssentia Taipei, Taiwan | |
Taiwan-based biopharmaceutical company making biologics for hematology and oncology, including an approved interferon therapy for polycythemia vera. | Booth Exhibiting at Booth 3739 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Show Me the Data™: Emerging Evidence and Evolving Clinical Practice in Essential Thrombocythemia and Polycythemia Vera Newer options for polycythemia vera and essential thrombocythemia, such as ropeginterferon and rusfertide, and what to do when hydroxyurea fails. Symposium Fri Dec 11 3:00pm–6:00pm Cases and Conversations: Applying Emerging Evidence to Real-World Care in Myeloproliferative Neoplasms Choosing among new myeloproliferative neoplasm drugs, including Janus kinase and telomerase inhibitors, hepcidin mimetics, and calreticulin-targeted antibodies. Talk Sun Dec 13 8:00am–9:00am |
Find decision makers at PharmaEssentia
Tell us what you sell and we’ll find the people at PharmaEssentia most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction